Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target. Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.
Keywords: FAP, DPP4, dipeptidyl peptidase, prolyl peptidase, inhibitor, cancer
Rights & PermissionsPrintExport
Published on: 01 March, 2012
Page: [719 - 727]